Replies to post #7408 on Relief Therapeutics Holding AG (RLFTF)

[mikar]

The major difference being Novavax has 62 million shares OS, Relief has 2 billion. At $23 Relief would have a market cap over $50 billion. Don’t think so!!

[trademax42]

Potential share price valuation $18

How many doses will be required globally? If, over the course of the pandemic (estimated at 5 years), only 1% of the world's population (76 Million people) will require dosing with RLF-100, either to prevent worsening of their condition, to recover from a critical condition, or even as a prophylaxis, that would equal 228 Million doses (at an average of 3 doses per patient). If each treatment dose results in only $50 to Relief Therapeutics net, that equals $11.4 Billion in net income over 5 years, or $2.28 Billion per year on average. Assuming dilution of 600 million more shares and applying a price to earnings ratio of 18 on that and you have a share price of around $18 per share

I believe 1% number over 5 years is very conservative, imo

"Relief Therapeutics Discovers A Promising COVID-19 Killer" August 11, 2020

https://seekingalpha.com/article/4367483-relief-therapeutics-discovers-promising-covidminus-19-killer


Quote from your post:

If you apply that to RLFTF and use todays price (yes I know we're up 1000% already). From $.5435 you would have a share price of $23.91.

$RLFTF

Disclaimer: This is just in my opinion, not intended for investment advice. Do your own dd and base your decision on your own dd.